|
You are here: Home: BCU 8| 2002: A CME Audio Series and Activity
Breast Cancer Update: A CME Audio Series and
Activity
Statement of Need /Target Audience
Breast cancer is one of the most rapidly evolving fields in medical
oncology. Published results from a plethora of ongoing clinical
trials lead to the continuous emergence of new therapeutic agents
and changes in the indications for existing treatments. In order
to offer optimal patient care — including the option of clinical
trial participation — the practicing medical oncologist must
be well informed of these advances.
To bridge the gap between research and patient care, Breast Cancer
Update utilizes one-on-one discussions with leading oncology investigators.
By providing access to the latest research developments and expert
perspectives, this CME program assists medical oncologists in the
formulation of up-to-date clinical management strategies.
Issue 8, 2002 of Breast Cancer Update consists of an in-depth
interview with oncology research leader Dennis Slamon. This activity
will review a variety of topics including the clinical development
of trastuzumab, synergy between trastuzumab and chemotherapy, trastuzumab-related
cardiotoxicity, combinations of trastuzumab with chemo/hormonal
therapies, optimal duration of trastuzumab therapy, clinical trials
and nonprotocol use of adjuvant trastuzumab, trials of trastuzumab
in the neoadjuvant setting and the optimal method to assess HER2
status.
Educational Objectives
Upon completion of this activity, participants should be
able to:
- More effectively utilize chemotherapy/trastuzumab combinations
in appropriate patients with HER2-positive metastatic breast cancer.
- More effectively discern the risk of cardiotoxicity associated
with various trastuzumabcontaining regimens and apply this knowledge
when choosing chemotherapeutic agents to minimize the potential
for cardiotoxicity in your patients.
- Develop a more effective algorithm to assess HER2 status and
utilize this in selecting appropriate candidates for trastuzumab
therapy.
Accreditation Statement
This activity has been planned and implemented in accordance
with the Essential Areas and Policies of the Accreditation Council
for Continuing Medical Education (ACCME) through the joint sponsorship
of the Postgraduate Institute for Medicine and NL Communications,
Inc. The Postgraduate Institute for Medicine is accredited by the
ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Postgraduate Institute for Medicine designates this educational
activity for a maximum of 1.5 hours in category 1 credit toward
the AMA Physician's Recognition Award. Each physician should claim
only credits that he/she actually spent in the activity.
Faculty Disclosure Statements
The Postgraduate Institute for Medicine has a conflict of interest
policy that requires course faculty to disclose any real or apparent
commercial financial affiliations related to the content of their
presentations/materials. It is not assumed that these financial
interests or affiliations will have an adverse impact on faculty
presentations; they are simply noted in this supplement to fully
inform participants.
|
